

The following listing of claims is to replace all previous claims listing. Amendments are indicated with added material being underlined and deleted material being ~~struck through~~.

1. (Currently Amended) A room-temperature stable injectable solution for veterinary use comprising from [0.5] 0.25 to 30% (w/v) of Carprofen (~~6-chloro- $\alpha$ -methyl-carbazole-2-acetic acid~~) (6-chloro-x -methyl-carbazole-2-acetic acid) or a physiologically acceptable salt of Carprofen, and from ~~2.4% to 12%~~ 0.5 to 20% (w/v) of a poloxamer, and water *q.s.* for injection.
2. (Original) An injectable aqueous solution according to claim 1, wherein the Carprofen salt is in the form of an arginine salt.
3. (Original) An injectable aqueous solution according to claim 1, wherein the Carprofen salt is in the form of a lysine salt.
4. (Previously Presented) An injectable aqueous solution according to claim 1, wherein Carprofen is present in an amount of from 2.5 to 7.5% (w/v).
5. (Previously Presented) An injectable aqueous solution according to claim 1, wherein Carprofen is present in an amount of from 2.5 to 5% (w/v).

6. (Previously Presented) An injectable aqueous solution according to claim 1, comprising arginine in an amount of from 1 to 20% (w/v).

7. (Original) An injectable aqueous solution according to claim 1, wherein an organic solvent is present with the poloxamer.

8. (Original) An injectable aqueous solution according to claim 7, wherein the organic solvent is present in the range of 0.5 to 20% (w/v).

9. (Original) An injectable aqueous solution according to claim 1, wherein the poloxamer is  $\text{HO}(\text{CH}_2\text{CH}_2\text{O})_x(\text{CCH}_3\text{HCH}_2\text{O})_y(\text{CH}_2\text{CH}_2)_z\text{H}$  wherein x is 75, y is 30 and z is 75.

10-11. (Cancelled)

12. (Currently Amended) A method of producing a room-temperature stable injectable aqueous solution for veterinary use comprising bringing together Carprofen or a physiologically acceptable salt thereof, a poloxamer, and adding sufficient water for injection, to provide a solution containing from [0.5] 0.25 to 30% (w/v) of Carprofen (~~6-chloro- $\alpha$ -methyl-carbazole-2-acetic acid~~) (6-chloro-x-methyl-carbazole-2-acetic acid) or a physiologically acceptable salt of Carprofen, and from ~~2.4% to 12%~~ 0.5% to 20% (w/v) of poloxamer.

13. (Original) A method according to claim 12, wherein the ploxamer is  $\text{HO}(\text{CH}_2\text{CH}_2\text{O})_x(\text{CCH}_3\text{HCH}_2\text{O})_y(\text{CH}_2\text{CH}_2)_z\text{H}$  wherein x is 75, y is 30 and z is 75.

14. (Previously Presented) A method of producing an injectable aqueous solution according to claim 12, wherein said method further comprises the inclusion of a preservative.

15. (Currently Amended) An injectable aqueous solution for veterinary use ~~according to Example 1 hereinbefore~~ comprising Carprofen 5.0% w/v, arginine 3.1% w/v, poloxamer 5.0% w/v, preservative 0.15% w/v and water *q.s.*

16. (Currently Amended) A method of producing an injectable aqueous solution ~~substantially as described in the Example 1~~ comprising bringing together Carprofen 5.0% w/v, arginine 3.1% w/v, poloxamer 5.0% w/v, preservative 0.15% w/v and water *q.s.* to form a mixture.

17. (Previously Presented) A method of producing an injectable aqueous solution according to claim 13, wherein said method further comprises the inclusion of a preservative.

18. (New) An injectable aqueous solution according to claim 1, comprising from about 0.5 to about 30% (w/v) of Carprofen (6-chloro-x-methyl-carbazole-2-acetic acid) or a physiologically acceptable salt of Carprofen.

19. (New) A method of treating inflammation felines comprising administering the injectable aqueous anti-inflammatory solution of claim 1.